Ovarian Serous Cystadenocarcinoma: Correlation between molecular cancer subtypes and selected clinical features

Maintained by TCGA GDAC Team (Broad Institute/MD Anderson Cancer Center/Harvard Medical School)

Overview

Introduction

This pipeline computes the correlation between cancer subtypes identified by different molecular patterns and selected clinical features.

Summary

Testing the association between subtypes identified by 12 different clustering approaches and 6 clinical features across 578 patients, 13 significant findings detected with P value < 0.05.

CNMF clustering analysis on array-based mRNA expression data identified 3 subtypes that correlate to 'Time to Death', 'AGE', and 'TUMOR.STAGE'.
Consensus hierarchical clustering analysis on array-based mRNA expression data identified 3 subtypes that correlate to 'AGE'.
CNMF clustering analysis on array-based miR expression data identified 3 subtypes that do not correlate to any clinical features.
Consensus hierarchical clustering analysis on array-based miR expression data identified 6 subtypes that correlate to 'AGE' and 'TUMOR.STAGE'.
3 subtypes identified in current cancer cohort by 'CN CNMF'. These subtypes correlate to 'AGE'.
3 subtypes identified in current cancer cohort by 'METHLYATION CNMF'. These subtypes correlate to 'AGE'.
CNMF clustering analysis on RPPA data identified 3 subtypes that correlate to 'Time to Death'.
Consensus hierarchical clustering analysis on RPPA data identified 4 subtypes that correlate to 'AGE'.
CNMF clustering analysis on sequencing-based mRNA expression data identified 3 subtypes that correlate to 'AGE'.
Consensus hierarchical clustering analysis on sequencing-based mRNA expression data identified 3 subtypes that correlate to 'AGE'.
CNMF clustering analysis on sequencing-based miR expression data identified 3 subtypes that correlate to 'Time to Death'.
Consensus hierarchical clustering analysis on sequencing-based miR expression data identified 3 subtypes that do not correlate to any clinical features.

Results

Overview of the results

Table 1. Get Full Table Overview of the association between subtypes identified by 12 different clustering approaches and 6 clinical features. Shown in the table are P values from statistical tests. Thresholded by P value < 0.05, 13 significant findings detected.


Clinical Features	Time to Death	AGE	PRIMARY SITE OF DISEASE	KARNOFSKY PERFORMANCE SCORE	TUMOR STAGE	RADIATIONS RADIATION REGIMENINDICATION
Statistical Tests	logrank test	ANOVA	Chi-square test	ANOVA	Chi-square test	Fisher's exact test
mRNA CNMF subtypes	0.0275	0.0107	0.568	0.151	0.0364	0.793
mRNA cHierClus subtypes	0.802	0.00529	0.224	0.172	0.266	0.611
miR CNMF subtypes	0.0543	0.622	0.198	0.737	0.126	0.266
miR cHierClus subtypes	0.607	0.00948	0.837	0.0822	0.00314	0.525
CN CNMF	0.423	7.91e-09	0.288	0.544	0.131	0.395
METHLYATION CNMF	0.198	3.66e-10	0.387	0.637	0.29	1
RPPA CNMF subtypes	0.0056	0.58	0.885	0.61	0.333	0.129
RPPA cHierClus subtypes	0.174	0.0408	0.676	0.68	0.181	0.823
RNAseq CNMF subtypes	0.247	0.00506	1	0.104	0.589	1
RNAseq cHierClus subtypes	0.73	0.0371	0.592	0.104	0.456	0.675
MIRseq CNMF subtypes	0.0431	0.594	0.0583	0.207	0.193	0.476
MIRseq cHierClus subtypes	0.563	0.757	0.812	0.577	0.49	0.281

Clustering Approach #1: 'mRNA CNMF subtypes'

Table S1. Get Full Table Description of clustering approach #1: 'mRNA CNMF subtypes'

Cluster Labels	1	2	3
Number of samples	219	211	132

'mRNA CNMF subtypes' versus 'Time to Death'

P value = 0.0275 (logrank test)

Table S2. Clustering Approach #1: 'mRNA CNMF subtypes' versus Clinical Feature #1: 'Time to Death'

	nPatients	nDeath	Duration Range (Median), Month
ALL	557	290	0.3 - 180.2 (28.3)
subtype1	216	125	0.3 - 152.0 (29.6)
subtype2	209	90	0.4 - 180.2 (27.0)
subtype3	132	75	0.3 - 119.1 (26.7)

Figure S1. Get High-res Image Clustering Approach #1: 'mRNA CNMF subtypes' versus Clinical Feature #1: 'Time to Death'

'mRNA CNMF subtypes' versus 'AGE'

P value = 0.0107 (ANOVA)

Table S3. Clustering Approach #1: 'mRNA CNMF subtypes' versus Clinical Feature #2: 'AGE'

	nPatients	Mean (Std.Dev)
ALL	551	59.7 (11.6)
subtype1	213	61.4 (11.5)
subtype2	207	58.0 (11.4)
subtype3	131	59.7 (11.8)

Figure S2. Get High-res Image Clustering Approach #1: 'mRNA CNMF subtypes' versus Clinical Feature #2: 'AGE'

'mRNA CNMF subtypes' versus 'PRIMARY.SITE.OF.DISEASE'

P value = 0.568 (Chi-square test)

Table S4. Clustering Approach #1: 'mRNA CNMF subtypes' versus Clinical Feature #3: 'PRIMARY.SITE.OF.DISEASE'

nPatients	OMENTUM	OVARY	PERITONEUM (OVARY)
ALL	2	558	2
subtype1	0	219	0
subtype2	1	209	1
subtype3	1	130	1

Figure S3. Get High-res Image Clustering Approach #1: 'mRNA CNMF subtypes' versus Clinical Feature #3: 'PRIMARY.SITE.OF.DISEASE'

'mRNA CNMF subtypes' versus 'KARNOFSKY.PERFORMANCE.SCORE'

P value = 0.151 (ANOVA)

Table S5. Clustering Approach #1: 'mRNA CNMF subtypes' versus Clinical Feature #4: 'KARNOFSKY.PERFORMANCE.SCORE'

	nPatients	Mean (Std.Dev)
ALL	78	75.6 (12.8)
subtype1	30	78.0 (13.2)
subtype2	28	76.4 (12.2)
subtype3	20	71.0 (12.1)

Figure S4. Get High-res Image Clustering Approach #1: 'mRNA CNMF subtypes' versus Clinical Feature #4: 'KARNOFSKY.PERFORMANCE.SCORE'

'mRNA CNMF subtypes' versus 'TUMOR.STAGE'

P value = 0.0364 (Chi-square test)

Table S6. Clustering Approach #1: 'mRNA CNMF subtypes' versus Clinical Feature #5: 'TUMOR.STAGE'

nPatients	I	II	III	IV
ALL	16	26	431	85
subtype1	7	9	173	28
subtype2	9	15	153	33
subtype3	0	2	105	24

Figure S5. Get High-res Image Clustering Approach #1: 'mRNA CNMF subtypes' versus Clinical Feature #5: 'TUMOR.STAGE'

'mRNA CNMF subtypes' versus 'RADIATIONS.RADIATION.REGIMENINDICATION'

P value = 0.793 (Fisher's exact test)

Table S7. Clustering Approach #1: 'mRNA CNMF subtypes' versus Clinical Feature #6: 'RADIATIONS.RADIATION.REGIMENINDICATION'

nPatients	NO	YES
ALL	3	559
subtype1	2	217
subtype2	1	210
subtype3	0	132

Figure S6. Get High-res Image Clustering Approach #1: 'mRNA CNMF subtypes' versus Clinical Feature #6: 'RADIATIONS.RADIATION.REGIMENINDICATION'

Clustering Approach #2: 'mRNA cHierClus subtypes'

Table S8. Get Full Table Description of clustering approach #2: 'mRNA cHierClus subtypes'

Cluster Labels	1	2	3
Number of samples	233	202	127

'mRNA cHierClus subtypes' versus 'Time to Death'

P value = 0.802 (logrank test)

Table S9. Clustering Approach #2: 'mRNA cHierClus subtypes' versus Clinical Feature #1: 'Time to Death'

	nPatients	nDeath	Duration Range (Median), Month
ALL	557	290	0.3 - 180.2 (28.3)
subtype1	232	111	0.3 - 119.1 (24.2)
subtype2	199	113	0.3 - 152.0 (30.0)
subtype3	126	66	0.3 - 180.2 (31.5)

Figure S7. Get High-res Image Clustering Approach #2: 'mRNA cHierClus subtypes' versus Clinical Feature #1: 'Time to Death'

'mRNA cHierClus subtypes' versus 'AGE'

P value = 0.00529 (ANOVA)

Table S10. Clustering Approach #2: 'mRNA cHierClus subtypes' versus Clinical Feature #2: 'AGE'

	nPatients	Mean (Std.Dev)
ALL	551	59.7 (11.6)
subtype1	231	58.5 (11.6)
subtype2	195	61.9 (11.8)
subtype3	125	58.7 (11.0)

Figure S8. Get High-res Image Clustering Approach #2: 'mRNA cHierClus subtypes' versus Clinical Feature #2: 'AGE'

'mRNA cHierClus subtypes' versus 'PRIMARY.SITE.OF.DISEASE'

P value = 0.224 (Chi-square test)

Table S11. Clustering Approach #2: 'mRNA cHierClus subtypes' versus Clinical Feature #3: 'PRIMARY.SITE.OF.DISEASE'

nPatients	OMENTUM	OVARY	PERITONEUM (OVARY)
ALL	2	558	2
subtype1	2	229	2
subtype2	0	202	0
subtype3	0	127	0

Figure S9. Get High-res Image Clustering Approach #2: 'mRNA cHierClus subtypes' versus Clinical Feature #3: 'PRIMARY.SITE.OF.DISEASE'

'mRNA cHierClus subtypes' versus 'KARNOFSKY.PERFORMANCE.SCORE'

P value = 0.172 (ANOVA)

Table S12. Clustering Approach #2: 'mRNA cHierClus subtypes' versus Clinical Feature #4: 'KARNOFSKY.PERFORMANCE.SCORE'

	nPatients	Mean (Std.Dev)
ALL	78	75.6 (12.8)
subtype1	29	73.1 (12.3)
subtype2	20	80.0 (14.5)
subtype3	29	75.2 (11.5)

Figure S10. Get High-res Image Clustering Approach #2: 'mRNA cHierClus subtypes' versus Clinical Feature #4: 'KARNOFSKY.PERFORMANCE.SCORE'

'mRNA cHierClus subtypes' versus 'TUMOR.STAGE'

P value = 0.266 (Chi-square test)

Table S13. Clustering Approach #2: 'mRNA cHierClus subtypes' versus Clinical Feature #5: 'TUMOR.STAGE'

nPatients	I	II	III	IV
ALL	16	26	431	85
subtype1	4	13	179	36
subtype2	7	9	160	23
subtype3	5	4	92	26

Figure S11. Get High-res Image Clustering Approach #2: 'mRNA cHierClus subtypes' versus Clinical Feature #5: 'TUMOR.STAGE'

'mRNA cHierClus subtypes' versus 'RADIATIONS.RADIATION.REGIMENINDICATION'

P value = 0.611 (Fisher's exact test)

Table S14. Clustering Approach #2: 'mRNA cHierClus subtypes' versus Clinical Feature #6: 'RADIATIONS.RADIATION.REGIMENINDICATION'

nPatients	NO	YES
ALL	3	559
subtype1	1	232
subtype2	2	200
subtype3	0	127

Figure S12. Get High-res Image Clustering Approach #2: 'mRNA cHierClus subtypes' versus Clinical Feature #6: 'RADIATIONS.RADIATION.REGIMENINDICATION'

Clustering Approach #3: 'miR CNMF subtypes'

Table S15. Get Full Table Description of clustering approach #3: 'miR CNMF subtypes'

Cluster Labels	1	2	3
Number of samples	157	165	238

'miR CNMF subtypes' versus 'Time to Death'

P value = 0.0543 (logrank test)

Table S16. Clustering Approach #3: 'miR CNMF subtypes' versus Clinical Feature #1: 'Time to Death'

	nPatients	nDeath	Duration Range (Median), Month
ALL	555	290	0.3 - 180.2 (28.2)
subtype1	156	86	0.3 - 130.0 (26.4)
subtype2	162	91	0.3 - 115.9 (24.7)
subtype3	237	113	0.3 - 180.2 (30.1)

Figure S13. Get High-res Image Clustering Approach #3: 'miR CNMF subtypes' versus Clinical Feature #1: 'Time to Death'

'miR CNMF subtypes' versus 'AGE'

P value = 0.622 (ANOVA)

Table S17. Clustering Approach #3: 'miR CNMF subtypes' versus Clinical Feature #2: 'AGE'

	nPatients	Mean (Std.Dev)
ALL	549	59.7 (11.6)
subtype1	153	59.3 (12.5)
subtype2	162	59.3 (11.6)
subtype3	234	60.3 (11.1)

Figure S14. Get High-res Image Clustering Approach #3: 'miR CNMF subtypes' versus Clinical Feature #2: 'AGE'

'miR CNMF subtypes' versus 'PRIMARY.SITE.OF.DISEASE'

P value = 0.198 (Chi-square test)

Table S18. Clustering Approach #3: 'miR CNMF subtypes' versus Clinical Feature #3: 'PRIMARY.SITE.OF.DISEASE'

nPatients	OMENTUM	OVARY	PERITONEUM (OVARY)
ALL	2	556	2
subtype1	0	155	2
subtype2	1	164	0
subtype3	1	237	0

Figure S15. Get High-res Image Clustering Approach #3: 'miR CNMF subtypes' versus Clinical Feature #3: 'PRIMARY.SITE.OF.DISEASE'

'miR CNMF subtypes' versus 'KARNOFSKY.PERFORMANCE.SCORE'

P value = 0.737 (ANOVA)

Table S19. Clustering Approach #3: 'miR CNMF subtypes' versus Clinical Feature #4: 'KARNOFSKY.PERFORMANCE.SCORE'

	nPatients	Mean (Std.Dev)
ALL	78	75.6 (12.8)
subtype1	24	76.7 (12.7)
subtype2	23	73.9 (15.3)
subtype3	31	76.1 (10.9)

Figure S16. Get High-res Image Clustering Approach #3: 'miR CNMF subtypes' versus Clinical Feature #4: 'KARNOFSKY.PERFORMANCE.SCORE'

'miR CNMF subtypes' versus 'TUMOR.STAGE'

P value = 0.126 (Chi-square test)

Table S20. Clustering Approach #3: 'miR CNMF subtypes' versus Clinical Feature #5: 'TUMOR.STAGE'

nPatients	I	II	III	IV
ALL	16	25	430	85
subtype1	3	6	114	32
subtype2	7	5	135	17
subtype3	6	14	181	36

Figure S17. Get High-res Image Clustering Approach #3: 'miR CNMF subtypes' versus Clinical Feature #5: 'TUMOR.STAGE'

'miR CNMF subtypes' versus 'RADIATIONS.RADIATION.REGIMENINDICATION'

P value = 0.266 (Fisher's exact test)

Table S21. Clustering Approach #3: 'miR CNMF subtypes' versus Clinical Feature #6: 'RADIATIONS.RADIATION.REGIMENINDICATION'

nPatients	NO	YES
ALL	3	557
subtype1	0	157
subtype2	0	165
subtype3	3	235

Figure S18. Get High-res Image Clustering Approach #3: 'miR CNMF subtypes' versus Clinical Feature #6: 'RADIATIONS.RADIATION.REGIMENINDICATION'

Clustering Approach #4: 'miR cHierClus subtypes'

Table S22. Get Full Table Description of clustering approach #4: 'miR cHierClus subtypes'

Cluster Labels	1	2	3	4	5	6
Number of samples	66	120	122	102	56	94

'miR cHierClus subtypes' versus 'Time to Death'

P value = 0.607 (logrank test)

Table S23. Clustering Approach #4: 'miR cHierClus subtypes' versus Clinical Feature #1: 'Time to Death'

	nPatients	nDeath	Duration Range (Median), Month
ALL	555	290	0.3 - 180.2 (28.2)
subtype1	65	31	0.8 - 115.9 (26.9)
subtype2	119	65	1.0 - 180.2 (28.7)
subtype3	122	65	0.3 - 130.0 (25.5)
subtype4	102	46	0.3 - 125.7 (29.6)
subtype5	54	31	1.8 - 106.0 (22.4)
subtype6	93	52	0.5 - 152.0 (30.4)

Figure S19. Get High-res Image Clustering Approach #4: 'miR cHierClus subtypes' versus Clinical Feature #1: 'Time to Death'

'miR cHierClus subtypes' versus 'AGE'

P value = 0.00948 (ANOVA)

Table S24. Clustering Approach #4: 'miR cHierClus subtypes' versus Clinical Feature #2: 'AGE'

	nPatients	Mean (Std.Dev)
ALL	549	59.7 (11.6)
subtype1	66	56.5 (11.2)
subtype2	119	57.9 (11.2)
subtype3	118	59.9 (12.3)
subtype4	100	60.1 (10.8)
subtype5	56	62.2 (13.2)
subtype6	90	62.2 (10.6)

Figure S20. Get High-res Image Clustering Approach #4: 'miR cHierClus subtypes' versus Clinical Feature #2: 'AGE'

'miR cHierClus subtypes' versus 'PRIMARY.SITE.OF.DISEASE'

P value = 0.837 (Chi-square test)

Table S25. Clustering Approach #4: 'miR cHierClus subtypes' versus Clinical Feature #3: 'PRIMARY.SITE.OF.DISEASE'

nPatients	OMENTUM	OVARY	PERITONEUM (OVARY)
ALL	2	556	2
subtype1	0	66	0
subtype2	1	118	1
subtype3	0	121	1
subtype4	1	101	0
subtype5	0	56	0
subtype6	0	94	0

Figure S21. Get High-res Image Clustering Approach #4: 'miR cHierClus subtypes' versus Clinical Feature #3: 'PRIMARY.SITE.OF.DISEASE'

'miR cHierClus subtypes' versus 'KARNOFSKY.PERFORMANCE.SCORE'

P value = 0.0822 (ANOVA)

Table S26. Clustering Approach #4: 'miR cHierClus subtypes' versus Clinical Feature #4: 'KARNOFSKY.PERFORMANCE.SCORE'

	nPatients	Mean (Std.Dev)
ALL	78	75.6 (12.8)
subtype1	9	75.6 (13.3)
subtype2	19	75.8 (12.6)
subtype3	17	76.5 (14.6)
subtype4	17	76.5 (10.6)
subtype5	5	88.0 (11.0)
subtype6	11	67.3 (10.1)

Figure S22. Get High-res Image Clustering Approach #4: 'miR cHierClus subtypes' versus Clinical Feature #4: 'KARNOFSKY.PERFORMANCE.SCORE'

'miR cHierClus subtypes' versus 'TUMOR.STAGE'

P value = 0.00314 (Chi-square test)

Table S27. Clustering Approach #4: 'miR cHierClus subtypes' versus Clinical Feature #5: 'TUMOR.STAGE'

nPatients	I	II	III	IV
ALL	16	25	430	85
subtype1	5	1	48	12
subtype2	0	0	98	21
subtype3	2	7	91	21
subtype4	5	7	73	17
subtype5	1	3	40	11
subtype6	3	7	80	3

Figure S23. Get High-res Image Clustering Approach #4: 'miR cHierClus subtypes' versus Clinical Feature #5: 'TUMOR.STAGE'

'miR cHierClus subtypes' versus 'RADIATIONS.RADIATION.REGIMENINDICATION'

P value = 0.525 (Chi-square test)

Table S28. Clustering Approach #4: 'miR cHierClus subtypes' versus Clinical Feature #6: 'RADIATIONS.RADIATION.REGIMENINDICATION'

nPatients	NO	YES
ALL	3	557
subtype1	0	66
subtype2	0	120
subtype3	0	122
subtype4	1	101
subtype5	1	55
subtype6	1	93

Figure S24. Get High-res Image Clustering Approach #4: 'miR cHierClus subtypes' versus Clinical Feature #6: 'RADIATIONS.RADIATION.REGIMENINDICATION'

Clustering Approach #5: 'CN CNMF'

Table S29. Get Full Table Description of clustering approach #5: 'CN CNMF'

Cluster Labels	1	2	3
Number of samples	162	204	186

'CN CNMF' versus 'Time to Death'

P value = 0.423 (logrank test)

Table S30. Clustering Approach #5: 'CN CNMF' versus Clinical Feature #1: 'Time to Death'

	nPatients	nDeath	Duration Range (Median), Month
ALL	546	283	0.3 - 180.2 (28.3)
subtype1	160	90	0.8 - 119.1 (29.3)
subtype2	202	98	0.3 - 130.0 (30.0)
subtype3	184	95	0.3 - 180.2 (22.3)

Figure S25. Get High-res Image Clustering Approach #5: 'CN CNMF' versus Clinical Feature #1: 'Time to Death'

'CN CNMF' versus 'AGE'

P value = 7.91e-09 (ANOVA)

Table S31. Clustering Approach #5: 'CN CNMF' versus Clinical Feature #2: 'AGE'

	nPatients	Mean (Std.Dev)
ALL	541	59.8 (11.6)
subtype1	158	59.5 (12.4)
subtype2	203	56.6 (10.9)
subtype3	180	63.7 (10.5)

Figure S26. Get High-res Image Clustering Approach #5: 'CN CNMF' versus Clinical Feature #2: 'AGE'

'CN CNMF' versus 'PRIMARY.SITE.OF.DISEASE'

P value = 0.288 (Chi-square test)

Table S32. Clustering Approach #5: 'CN CNMF' versus Clinical Feature #3: 'PRIMARY.SITE.OF.DISEASE'

nPatients	OMENTUM	OVARY	PERITONEUM (OVARY)
ALL	2	548	2
subtype1	1	161	0
subtype2	1	203	0
subtype3	0	184	2

Figure S27. Get High-res Image Clustering Approach #5: 'CN CNMF' versus Clinical Feature #3: 'PRIMARY.SITE.OF.DISEASE'

'CN CNMF' versus 'KARNOFSKY.PERFORMANCE.SCORE'

P value = 0.544 (ANOVA)

Table S33. Clustering Approach #5: 'CN CNMF' versus Clinical Feature #4: 'KARNOFSKY.PERFORMANCE.SCORE'

	nPatients	Mean (Std.Dev)
ALL	76	75.5 (12.9)
subtype1	18	76.7 (10.3)
subtype2	31	73.5 (13.1)
subtype3	27	77.0 (14.4)

Figure S28. Get High-res Image Clustering Approach #5: 'CN CNMF' versus Clinical Feature #4: 'KARNOFSKY.PERFORMANCE.SCORE'

'CN CNMF' versus 'TUMOR.STAGE'

P value = 0.131 (Chi-square test)

Table S34. Clustering Approach #5: 'CN CNMF' versus Clinical Feature #5: 'TUMOR.STAGE'

nPatients	I	II	III	IV
ALL	16	26	423	82
subtype1	7	7	123	23
subtype2	4	10	149	41
subtype3	5	9	151	18

Figure S29. Get High-res Image Clustering Approach #5: 'CN CNMF' versus Clinical Feature #5: 'TUMOR.STAGE'

'CN CNMF' versus 'RADIATIONS.RADIATION.REGIMENINDICATION'

P value = 0.395 (Fisher's exact test)

Table S35. Clustering Approach #5: 'CN CNMF' versus Clinical Feature #6: 'RADIATIONS.RADIATION.REGIMENINDICATION'

nPatients	NO	YES
ALL	3	549
subtype1	1	161
subtype2	0	204
subtype3	2	184

Figure S30. Get High-res Image Clustering Approach #5: 'CN CNMF' versus Clinical Feature #6: 'RADIATIONS.RADIATION.REGIMENINDICATION'

Clustering Approach #6: 'METHLYATION CNMF'

Table S36. Get Full Table Description of clustering approach #6: 'METHLYATION CNMF'

Cluster Labels	1	2	3
Number of samples	174	181	219

'METHLYATION CNMF' versus 'Time to Death'

P value = 0.198 (logrank test)

Table S37. Clustering Approach #6: 'METHLYATION CNMF' versus Clinical Feature #1: 'Time to Death'

	nPatients	nDeath	Duration Range (Median), Month
ALL	557	291	0.3 - 180.2 (28.3)
subtype1	168	100	0.3 - 152.0 (26.9)
subtype2	173	86	0.8 - 180.2 (28.6)
subtype3	216	105	0.3 - 130.0 (28.7)

Figure S31. Get High-res Image Clustering Approach #6: 'METHLYATION CNMF' versus Clinical Feature #1: 'Time to Death'

'METHLYATION CNMF' versus 'AGE'

P value = 3.66e-10 (ANOVA)

Table S38. Clustering Approach #6: 'METHLYATION CNMF' versus Clinical Feature #2: 'AGE'

	nPatients	Mean (Std.Dev)
ALL	553	59.8 (11.6)
subtype1	167	64.6 (10.6)
subtype2	171	57.6 (12.0)
subtype3	215	57.8 (10.9)

Figure S32. Get High-res Image Clustering Approach #6: 'METHLYATION CNMF' versus Clinical Feature #2: 'AGE'

'METHLYATION CNMF' versus 'PRIMARY.SITE.OF.DISEASE'

P value = 0.387 (Chi-square test)

Table S39. Clustering Approach #6: 'METHLYATION CNMF' versus Clinical Feature #3: 'PRIMARY.SITE.OF.DISEASE'

nPatients	OMENTUM	OVARY	PERITONEUM (OVARY)
ALL	2	560	2
subtype1	0	169	1
subtype2	0	176	0
subtype3	2	215	1

Figure S33. Get High-res Image Clustering Approach #6: 'METHLYATION CNMF' versus Clinical Feature #3: 'PRIMARY.SITE.OF.DISEASE'

'METHLYATION CNMF' versus 'KARNOFSKY.PERFORMANCE.SCORE'

P value = 0.637 (ANOVA)

Table S40. Clustering Approach #6: 'METHLYATION CNMF' versus Clinical Feature #4: 'KARNOFSKY.PERFORMANCE.SCORE'

	nPatients	Mean (Std.Dev)
ALL	78	75.6 (12.8)
subtype1	23	74.8 (13.8)
subtype2	20	74.0 (13.1)
subtype3	35	77.1 (12.0)

Figure S34. Get High-res Image Clustering Approach #6: 'METHLYATION CNMF' versus Clinical Feature #4: 'KARNOFSKY.PERFORMANCE.SCORE'

'METHLYATION CNMF' versus 'TUMOR.STAGE'

P value = 0.29 (Chi-square test)

Table S41. Clustering Approach #6: 'METHLYATION CNMF' versus Clinical Feature #5: 'TUMOR.STAGE'

nPatients	I	II	III	IV
ALL	16	26	430	86
subtype1	4	7	135	21
subtype2	3	5	134	32
subtype3	9	14	161	33

Figure S35. Get High-res Image Clustering Approach #6: 'METHLYATION CNMF' versus Clinical Feature #5: 'TUMOR.STAGE'

'METHLYATION CNMF' versus 'RADIATIONS.RADIATION.REGIMENINDICATION'

P value = 1 (Fisher's exact test)

Table S42. Clustering Approach #6: 'METHLYATION CNMF' versus Clinical Feature #6: 'RADIATIONS.RADIATION.REGIMENINDICATION'

nPatients	NO	YES
ALL	3	571
subtype1	1	173
subtype2	1	180
subtype3	1	218

Figure S36. Get High-res Image Clustering Approach #6: 'METHLYATION CNMF' versus Clinical Feature #6: 'RADIATIONS.RADIATION.REGIMENINDICATION'

Clustering Approach #7: 'RPPA CNMF subtypes'

Table S43. Get Full Table Description of clustering approach #7: 'RPPA CNMF subtypes'

Cluster Labels	1	2	3
Number of samples	128	207	72

'RPPA CNMF subtypes' versus 'Time to Death'

P value = 0.0056 (logrank test)

Table S44. Clustering Approach #7: 'RPPA CNMF subtypes' versus Clinical Feature #1: 'Time to Death'

	nPatients	nDeath	Duration Range (Median), Month
ALL	400	209	0.3 - 180.2 (28.6)
subtype1	125	71	0.4 - 125.7 (31.1)
subtype2	204	92	0.3 - 180.2 (25.2)
subtype3	71	46	0.5 - 89.3 (25.9)

Figure S37. Get High-res Image Clustering Approach #7: 'RPPA CNMF subtypes' versus Clinical Feature #1: 'Time to Death'

'RPPA CNMF subtypes' versus 'AGE'

P value = 0.58 (ANOVA)

Table S45. Clustering Approach #7: 'RPPA CNMF subtypes' versus Clinical Feature #2: 'AGE'

	nPatients	Mean (Std.Dev)
ALL	400	59.7 (11.8)
subtype1	126	60.0 (12.3)
subtype2	204	59.1 (11.7)
subtype3	70	60.7 (11.3)

Figure S38. Get High-res Image Clustering Approach #7: 'RPPA CNMF subtypes' versus Clinical Feature #2: 'AGE'

'RPPA CNMF subtypes' versus 'PRIMARY.SITE.OF.DISEASE'

P value = 0.885 (Chi-square test)

Table S46. Clustering Approach #7: 'RPPA CNMF subtypes' versus Clinical Feature #3: 'PRIMARY.SITE.OF.DISEASE'

nPatients	OMENTUM	OVARY	PERITONEUM (OVARY)
ALL	2	403	2
subtype1	1	126	1
subtype2	1	205	1
subtype3	0	72	0

Figure S39. Get High-res Image Clustering Approach #7: 'RPPA CNMF subtypes' versus Clinical Feature #3: 'PRIMARY.SITE.OF.DISEASE'

'RPPA CNMF subtypes' versus 'KARNOFSKY.PERFORMANCE.SCORE'

P value = 0.61 (ANOVA)

Table S47. Clustering Approach #7: 'RPPA CNMF subtypes' versus Clinical Feature #4: 'KARNOFSKY.PERFORMANCE.SCORE'

	nPatients	Mean (Std.Dev)
ALL	51	74.9 (11.9)
subtype1	19	76.8 (10.0)
subtype2	27	73.3 (13.6)
subtype3	5	76.0 (8.9)

Figure S40. Get High-res Image Clustering Approach #7: 'RPPA CNMF subtypes' versus Clinical Feature #4: 'KARNOFSKY.PERFORMANCE.SCORE'

'RPPA CNMF subtypes' versus 'TUMOR.STAGE'

P value = 0.333 (Chi-square test)

Table S48. Clustering Approach #7: 'RPPA CNMF subtypes' versus Clinical Feature #5: 'TUMOR.STAGE'

nPatients	I	II	III	IV
ALL	14	19	317	52
subtype1	4	7	96	20
subtype2	9	11	164	20
subtype3	1	1	57	12

Figure S41. Get High-res Image Clustering Approach #7: 'RPPA CNMF subtypes' versus Clinical Feature #5: 'TUMOR.STAGE'

'RPPA CNMF subtypes' versus 'RADIATIONS.RADIATION.REGIMENINDICATION'

P value = 0.129 (Fisher's exact test)

Table S49. Clustering Approach #7: 'RPPA CNMF subtypes' versus Clinical Feature #6: 'RADIATIONS.RADIATION.REGIMENINDICATION'

nPatients	NO	YES
ALL	2	405
subtype1	2	126
subtype2	0	207
subtype3	0	72

Figure S42. Get High-res Image Clustering Approach #7: 'RPPA CNMF subtypes' versus Clinical Feature #6: 'RADIATIONS.RADIATION.REGIMENINDICATION'

Clustering Approach #8: 'RPPA cHierClus subtypes'

Table S50. Get Full Table Description of clustering approach #8: 'RPPA cHierClus subtypes'

Cluster Labels	1	2	3	4
Number of samples	101	68	145	93

'RPPA cHierClus subtypes' versus 'Time to Death'

P value = 0.174 (logrank test)

Table S51. Clustering Approach #8: 'RPPA cHierClus subtypes' versus Clinical Feature #1: 'Time to Death'

	nPatients	nDeath	Duration Range (Median), Month
ALL	400	209	0.3 - 180.2 (28.6)
subtype1	97	45	0.3 - 115.9 (28.5)
subtype2	68	42	0.8 - 180.2 (35.5)
subtype3	143	84	0.4 - 125.7 (27.5)
subtype4	92	38	0.5 - 152.0 (22.6)

Figure S43. Get High-res Image Clustering Approach #8: 'RPPA cHierClus subtypes' versus Clinical Feature #1: 'Time to Death'

'RPPA cHierClus subtypes' versus 'AGE'

P value = 0.0408 (ANOVA)

Table S52. Clustering Approach #8: 'RPPA cHierClus subtypes' versus Clinical Feature #2: 'AGE'

	nPatients	Mean (Std.Dev)
ALL	400	59.7 (11.8)
subtype1	100	57.7 (11.8)
subtype2	67	61.5 (11.1)
subtype3	142	61.2 (12.1)
subtype4	91	58.2 (11.6)

Figure S44. Get High-res Image Clustering Approach #8: 'RPPA cHierClus subtypes' versus Clinical Feature #2: 'AGE'

'RPPA cHierClus subtypes' versus 'PRIMARY.SITE.OF.DISEASE'

P value = 0.676 (Chi-square test)

Table S53. Clustering Approach #8: 'RPPA cHierClus subtypes' versus Clinical Feature #3: 'PRIMARY.SITE.OF.DISEASE'

nPatients	OMENTUM	OVARY	PERITONEUM (OVARY)
ALL	2	403	2
subtype1	0	101	0
subtype2	1	67	0
subtype3	1	143	1
subtype4	0	92	1

Figure S45. Get High-res Image Clustering Approach #8: 'RPPA cHierClus subtypes' versus Clinical Feature #3: 'PRIMARY.SITE.OF.DISEASE'

'RPPA cHierClus subtypes' versus 'KARNOFSKY.PERFORMANCE.SCORE'

P value = 0.68 (ANOVA)

Table S54. Clustering Approach #8: 'RPPA cHierClus subtypes' versus Clinical Feature #4: 'KARNOFSKY.PERFORMANCE.SCORE'

	nPatients	Mean (Std.Dev)
ALL	51	74.9 (11.9)
subtype1	5	80.0 (0.0)
subtype2	9	75.6 (16.7)
subtype3	13	72.3 (10.1)
subtype4	24	75.0 (12.2)

Figure S46. Get High-res Image Clustering Approach #8: 'RPPA cHierClus subtypes' versus Clinical Feature #4: 'KARNOFSKY.PERFORMANCE.SCORE'

'RPPA cHierClus subtypes' versus 'TUMOR.STAGE'

P value = 0.181 (Chi-square test)

Table S55. Clustering Approach #8: 'RPPA cHierClus subtypes' versus Clinical Feature #5: 'TUMOR.STAGE'

nPatients	I	II	III	IV
ALL	14	19	317	52
subtype1	8	5	76	9
subtype2	2	4	53	9
subtype3	3	5	111	24
subtype4	1	5	77	10

Figure S47. Get High-res Image Clustering Approach #8: 'RPPA cHierClus subtypes' versus Clinical Feature #5: 'TUMOR.STAGE'

'RPPA cHierClus subtypes' versus 'RADIATIONS.RADIATION.REGIMENINDICATION'

P value = 0.823 (Fisher's exact test)

Table S56. Clustering Approach #8: 'RPPA cHierClus subtypes' versus Clinical Feature #6: 'RADIATIONS.RADIATION.REGIMENINDICATION'

nPatients	NO	YES
ALL	2	405
subtype1	0	101
subtype2	0	68
subtype3	1	144
subtype4	1	92

Figure S48. Get High-res Image Clustering Approach #8: 'RPPA cHierClus subtypes' versus Clinical Feature #6: 'RADIATIONS.RADIATION.REGIMENINDICATION'

Clustering Approach #9: 'RNAseq CNMF subtypes'

Table S57. Get Full Table Description of clustering approach #9: 'RNAseq CNMF subtypes'

Cluster Labels	1	2	3
Number of samples	100	70	92

'RNAseq CNMF subtypes' versus 'Time to Death'

P value = 0.247 (logrank test)

Table S58. Clustering Approach #9: 'RNAseq CNMF subtypes' versus Clinical Feature #1: 'Time to Death'

	nPatients	nDeath	Duration Range (Median), Month
ALL	260	147	0.3 - 180.2 (28.0)
subtype1	100	55	0.4 - 180.2 (27.7)
subtype2	69	37	1.0 - 116.1 (35.1)
subtype3	91	55	0.3 - 152.0 (25.0)

Figure S49. Get High-res Image Clustering Approach #9: 'RNAseq CNMF subtypes' versus Clinical Feature #1: 'Time to Death'

'RNAseq CNMF subtypes' versus 'AGE'

P value = 0.00506 (ANOVA)

Table S59. Clustering Approach #9: 'RNAseq CNMF subtypes' versus Clinical Feature #2: 'AGE'

	nPatients	Mean (Std.Dev)
ALL	255	59.0 (10.8)
subtype1	98	59.7 (10.6)
subtype2	68	55.5 (10.9)
subtype3	89	60.9 (10.6)

Figure S50. Get High-res Image Clustering Approach #9: 'RNAseq CNMF subtypes' versus Clinical Feature #2: 'AGE'

'RNAseq CNMF subtypes' versus 'PRIMARY.SITE.OF.DISEASE'

P value = 1 (Fisher's exact test)

Table S60. Clustering Approach #9: 'RNAseq CNMF subtypes' versus Clinical Feature #3: 'PRIMARY.SITE.OF.DISEASE'

nPatients	OMENTUM	OVARY
ALL	1	261
subtype1	1	99
subtype2	0	70
subtype3	0	92

Figure S51. Get High-res Image Clustering Approach #9: 'RNAseq CNMF subtypes' versus Clinical Feature #3: 'PRIMARY.SITE.OF.DISEASE'

'RNAseq CNMF subtypes' versus 'KARNOFSKY.PERFORMANCE.SCORE'

P value = 0.104 (ANOVA)

Table S61. Clustering Approach #9: 'RNAseq CNMF subtypes' versus Clinical Feature #4: 'KARNOFSKY.PERFORMANCE.SCORE'

	nPatients	Mean (Std.Dev)
ALL	14	74.3 (12.2)
subtype1	10	72.0 (14.0)
subtype2	1	80.0 (NA)
subtype3	3	80.0 (0.0)

Figure S52. Get High-res Image Clustering Approach #9: 'RNAseq CNMF subtypes' versus Clinical Feature #4: 'KARNOFSKY.PERFORMANCE.SCORE'

'RNAseq CNMF subtypes' versus 'TUMOR.STAGE'

P value = 0.589 (Chi-square test)

Table S62. Clustering Approach #9: 'RNAseq CNMF subtypes' versus Clinical Feature #5: 'TUMOR.STAGE'

nPatients	II	III	IV
ALL	18	210	33
subtype1	7	79	14
subtype2	6	53	11
subtype3	5	78	8

Figure S53. Get High-res Image Clustering Approach #9: 'RNAseq CNMF subtypes' versus Clinical Feature #5: 'TUMOR.STAGE'

'RNAseq CNMF subtypes' versus 'RADIATIONS.RADIATION.REGIMENINDICATION'

P value = 1 (Fisher's exact test)

Table S63. Clustering Approach #9: 'RNAseq CNMF subtypes' versus Clinical Feature #6: 'RADIATIONS.RADIATION.REGIMENINDICATION'

nPatients	NO	YES
ALL	2	260
subtype1	1	99
subtype2	0	70
subtype3	1	91

Figure S54. Get High-res Image Clustering Approach #9: 'RNAseq CNMF subtypes' versus Clinical Feature #6: 'RADIATIONS.RADIATION.REGIMENINDICATION'

Clustering Approach #10: 'RNAseq cHierClus subtypes'

Table S64. Get Full Table Description of clustering approach #10: 'RNAseq cHierClus subtypes'

Cluster Labels	1	2	3
Number of samples	104	107	51

'RNAseq cHierClus subtypes' versus 'Time to Death'

P value = 0.73 (logrank test)

Table S65. Clustering Approach #10: 'RNAseq cHierClus subtypes' versus Clinical Feature #1: 'Time to Death'

	nPatients	nDeath	Duration Range (Median), Month
ALL	260	147	0.3 - 180.2 (28.0)
subtype1	103	54	0.4 - 180.2 (27.9)
subtype2	107	65	0.4 - 152.0 (28.3)
subtype3	50	28	0.3 - 115.9 (27.8)

Figure S55. Get High-res Image Clustering Approach #10: 'RNAseq cHierClus subtypes' versus Clinical Feature #1: 'Time to Death'

'RNAseq cHierClus subtypes' versus 'AGE'

P value = 0.0371 (ANOVA)

Table S66. Clustering Approach #10: 'RNAseq cHierClus subtypes' versus Clinical Feature #2: 'AGE'

	nPatients	Mean (Std.Dev)
ALL	255	59.0 (10.8)
subtype1	101	58.8 (10.2)
subtype2	104	60.7 (11.3)
subtype3	50	56.0 (10.6)

Figure S56. Get High-res Image Clustering Approach #10: 'RNAseq cHierClus subtypes' versus Clinical Feature #2: 'AGE'

'RNAseq cHierClus subtypes' versus 'PRIMARY.SITE.OF.DISEASE'

P value = 0.592 (Fisher's exact test)

Table S67. Clustering Approach #10: 'RNAseq cHierClus subtypes' versus Clinical Feature #3: 'PRIMARY.SITE.OF.DISEASE'

nPatients	OMENTUM	OVARY
ALL	1	261
subtype1	1	103
subtype2	0	107
subtype3	0	51

Figure S57. Get High-res Image Clustering Approach #10: 'RNAseq cHierClus subtypes' versus Clinical Feature #3: 'PRIMARY.SITE.OF.DISEASE'

'RNAseq cHierClus subtypes' versus 'KARNOFSKY.PERFORMANCE.SCORE'

P value = 0.104 (ANOVA)

Table S68. Clustering Approach #10: 'RNAseq cHierClus subtypes' versus Clinical Feature #4: 'KARNOFSKY.PERFORMANCE.SCORE'

	nPatients	Mean (Std.Dev)
ALL	14	74.3 (12.2)
subtype1	11	72.7 (13.5)
subtype2	3	80.0 (0.0)

Figure S58. Get High-res Image Clustering Approach #10: 'RNAseq cHierClus subtypes' versus Clinical Feature #4: 'KARNOFSKY.PERFORMANCE.SCORE'

'RNAseq cHierClus subtypes' versus 'TUMOR.STAGE'

P value = 0.456 (Chi-square test)

Table S69. Clustering Approach #10: 'RNAseq cHierClus subtypes' versus Clinical Feature #5: 'TUMOR.STAGE'

nPatients	II	III	IV
ALL	18	210	33
subtype1	6	85	13
subtype2	8	88	10
subtype3	4	37	10

Figure S59. Get High-res Image Clustering Approach #10: 'RNAseq cHierClus subtypes' versus Clinical Feature #5: 'TUMOR.STAGE'

'RNAseq cHierClus subtypes' versus 'RADIATIONS.RADIATION.REGIMENINDICATION'

P value = 0.675 (Fisher's exact test)

Table S70. Clustering Approach #10: 'RNAseq cHierClus subtypes' versus Clinical Feature #6: 'RADIATIONS.RADIATION.REGIMENINDICATION'

nPatients	NO	YES
ALL	2	260
subtype1	0	104
subtype2	2	105
subtype3	0	51

Figure S60. Get High-res Image Clustering Approach #10: 'RNAseq cHierClus subtypes' versus Clinical Feature #6: 'RADIATIONS.RADIATION.REGIMENINDICATION'

Clustering Approach #11: 'MIRseq CNMF subtypes'

Table S71. Get Full Table Description of clustering approach #11: 'MIRseq CNMF subtypes'

Cluster Labels	1	2	3
Number of samples	113	195	146

'MIRseq CNMF subtypes' versus 'Time to Death'

P value = 0.0431 (logrank test)

Table S72. Clustering Approach #11: 'MIRseq CNMF subtypes' versus Clinical Feature #1: 'Time to Death'

	nPatients	nDeath	Duration Range (Median), Month
ALL	451	252	0.3 - 180.2 (30.1)
subtype1	113	74	0.3 - 152.0 (27.0)
subtype2	194	101	0.3 - 180.2 (32.5)
subtype3	144	77	0.3 - 130.0 (28.7)

Figure S61. Get High-res Image Clustering Approach #11: 'MIRseq CNMF subtypes' versus Clinical Feature #1: 'Time to Death'

'MIRseq CNMF subtypes' versus 'AGE'

P value = 0.594 (ANOVA)

Table S73. Clustering Approach #11: 'MIRseq CNMF subtypes' versus Clinical Feature #2: 'AGE'

	nPatients	Mean (Std.Dev)
ALL	446	59.8 (11.5)
subtype1	112	60.8 (11.7)
subtype2	192	59.5 (11.3)
subtype3	142	59.5 (11.6)

Figure S62. Get High-res Image Clustering Approach #11: 'MIRseq CNMF subtypes' versus Clinical Feature #2: 'AGE'

'MIRseq CNMF subtypes' versus 'PRIMARY.SITE.OF.DISEASE'

P value = 0.0583 (Chi-square test)

Table S74. Clustering Approach #11: 'MIRseq CNMF subtypes' versus Clinical Feature #3: 'PRIMARY.SITE.OF.DISEASE'

nPatients	OMENTUM	OVARY	PERITONEUM (OVARY)
ALL	2	451	1
subtype1	2	110	1
subtype2	0	195	0
subtype3	0	146	0

Figure S63. Get High-res Image Clustering Approach #11: 'MIRseq CNMF subtypes' versus Clinical Feature #3: 'PRIMARY.SITE.OF.DISEASE'

'MIRseq CNMF subtypes' versus 'KARNOFSKY.PERFORMANCE.SCORE'

P value = 0.207 (ANOVA)

Table S75. Clustering Approach #11: 'MIRseq CNMF subtypes' versus Clinical Feature #4: 'KARNOFSKY.PERFORMANCE.SCORE'

	nPatients	Mean (Std.Dev)
ALL	64	75.3 (13.2)
subtype1	10	82.0 (14.8)
subtype2	46	74.3 (12.4)
subtype3	8	72.5 (14.9)

Figure S64. Get High-res Image Clustering Approach #11: 'MIRseq CNMF subtypes' versus Clinical Feature #4: 'KARNOFSKY.PERFORMANCE.SCORE'

'MIRseq CNMF subtypes' versus 'TUMOR.STAGE'

P value = 0.193 (Chi-square test)

Table S76. Clustering Approach #11: 'MIRseq CNMF subtypes' versus Clinical Feature #5: 'TUMOR.STAGE'

nPatients	II	III	IV
ALL	24	352	74
subtype1	4	91	17
subtype2	8	147	38
subtype3	12	114	19

Figure S65. Get High-res Image Clustering Approach #11: 'MIRseq CNMF subtypes' versus Clinical Feature #5: 'TUMOR.STAGE'

'MIRseq CNMF subtypes' versus 'RADIATIONS.RADIATION.REGIMENINDICATION'

P value = 0.476 (Fisher's exact test)

Table S77. Clustering Approach #11: 'MIRseq CNMF subtypes' versus Clinical Feature #6: 'RADIATIONS.RADIATION.REGIMENINDICATION'

nPatients	NO	YES
ALL	3	451
subtype1	0	113
subtype2	1	194
subtype3	2	144

Figure S66. Get High-res Image Clustering Approach #11: 'MIRseq CNMF subtypes' versus Clinical Feature #6: 'RADIATIONS.RADIATION.REGIMENINDICATION'

Clustering Approach #12: 'MIRseq cHierClus subtypes'

Table S78. Get Full Table Description of clustering approach #12: 'MIRseq cHierClus subtypes'

Cluster Labels	1	2	3
Number of samples	3	153	298

'MIRseq cHierClus subtypes' versus 'Time to Death'

P value = 0.563 (logrank test)

Table S79. Clustering Approach #12: 'MIRseq cHierClus subtypes' versus Clinical Feature #1: 'Time to Death'

	nPatients	nDeath	Duration Range (Median), Month
ALL	451	252	0.3 - 180.2 (30.1)
subtype1	3	3	4.5 - 60.6 (33.7)
subtype2	151	82	0.3 - 130.0 (28.6)
subtype3	297	167	0.3 - 180.2 (31.0)

Figure S67. Get High-res Image Clustering Approach #12: 'MIRseq cHierClus subtypes' versus Clinical Feature #1: 'Time to Death'

'MIRseq cHierClus subtypes' versus 'AGE'

P value = 0.757 (ANOVA)

Table S80. Clustering Approach #12: 'MIRseq cHierClus subtypes' versus Clinical Feature #2: 'AGE'

	nPatients	Mean (Std.Dev)
ALL	446	59.8 (11.5)
subtype1	3	62.7 (1.5)
subtype2	149	59.3 (11.9)
subtype3	294	60.0 (11.4)

Figure S68. Get High-res Image Clustering Approach #12: 'MIRseq cHierClus subtypes' versus Clinical Feature #2: 'AGE'

'MIRseq cHierClus subtypes' versus 'PRIMARY.SITE.OF.DISEASE'

P value = 0.812 (Chi-square test)

Table S81. Clustering Approach #12: 'MIRseq cHierClus subtypes' versus Clinical Feature #3: 'PRIMARY.SITE.OF.DISEASE'

nPatients	OMENTUM	OVARY	PERITONEUM (OVARY)
ALL	2	451	1
subtype1	0	3	0
subtype2	0	153	0
subtype3	2	295	1

Figure S69. Get High-res Image Clustering Approach #12: 'MIRseq cHierClus subtypes' versus Clinical Feature #3: 'PRIMARY.SITE.OF.DISEASE'

'MIRseq cHierClus subtypes' versus 'KARNOFSKY.PERFORMANCE.SCORE'

P value = 0.577 (ANOVA)

Table S82. Clustering Approach #12: 'MIRseq cHierClus subtypes' versus Clinical Feature #4: 'KARNOFSKY.PERFORMANCE.SCORE'

	nPatients	Mean (Std.Dev)
ALL	64	75.3 (13.2)
subtype2	8	72.5 (14.9)
subtype3	56	75.7 (13.1)

Figure S70. Get High-res Image Clustering Approach #12: 'MIRseq cHierClus subtypes' versus Clinical Feature #4: 'KARNOFSKY.PERFORMANCE.SCORE'

'MIRseq cHierClus subtypes' versus 'TUMOR.STAGE'

P value = 0.49 (Chi-square test)

Table S83. Clustering Approach #12: 'MIRseq cHierClus subtypes' versus Clinical Feature #5: 'TUMOR.STAGE'

nPatients	II	III	IV
ALL	24	352	74
subtype1	0	3	0
subtype2	11	120	21
subtype3	13	229	53

Figure S71. Get High-res Image Clustering Approach #12: 'MIRseq cHierClus subtypes' versus Clinical Feature #5: 'TUMOR.STAGE'

'MIRseq cHierClus subtypes' versus 'RADIATIONS.RADIATION.REGIMENINDICATION'

P value = 0.281 (Fisher's exact test)

Table S84. Clustering Approach #12: 'MIRseq cHierClus subtypes' versus Clinical Feature #6: 'RADIATIONS.RADIATION.REGIMENINDICATION'

nPatients	NO	YES
ALL	3	451
subtype1	0	3
subtype2	2	151
subtype3	1	297

Figure S72. Get High-res Image Clustering Approach #12: 'MIRseq cHierClus subtypes' versus Clinical Feature #6: 'RADIATIONS.RADIATION.REGIMENINDICATION'

Methods & Data

Input

Cluster data file = OV-TP.mergedcluster.txt
Clinical data file = OV-TP.clin.merged.picked.txt
Number of patients = 578
Number of clustering approaches = 12
Number of selected clinical features = 6
Exclude small clusters that include fewer than K patients, K = 3

Clustering approaches

CNMF clustering

consensus non-negative matrix factorization clustering approach (Brunet et al. 2004)

Consensus hierarchical clustering

Resampling-based clustering method (Monti et al. 2003)

Survival analysis

For survival clinical features, the Kaplan-Meier survival curves of tumors with and without gene mutations were plotted and the statistical significance P values were estimated by logrank test (Bland and Altman 2004) using the 'survdiff' function in R

ANOVA analysis

For continuous numerical clinical features, one-way analysis of variance (Howell 2002) was applied to compare the clinical values between tumor subtypes using 'anova' function in R

Chi-square test

For multi-class clinical features (nominal or ordinal), Chi-square tests (Greenwood and Nikulin 1996) were used to estimate the P values using the 'chisq.test' function in R

Fisher's exact test

For binary clinical features, two-tailed Fisher's exact tests (Fisher 1922) were used to estimate the P values using the 'fisher.test' function in R

Download Results

This is an experimental feature. The full results of the analysis summarized in this report can be downloaded from the TCGA Data Coordination Center.

References

[1] Brunet et al., Metagenes and molecular pattern discovery using matrix factorization, PNAS 101(12):4164-9 (2004)

[2] Monti et al., Consensus Clustering: A Resampling-Based Method for Class Discovery and Visualization of Gene Expression Microarray Data, Machine Learning 52(1):91-118 (2003)

[3] Bland and Altman, Statistics notes: The logrank test, BMJ 328(7447):1073 (2004)

[4] Howell, D, Statistical Methods for Psychology. (5th ed.), Duxbury Press:324-5 (2002)

[5] Greenwood and Nikulin, A guide to chi-squared testing, Wiley, New York. ISBN 047155779X (1996)

[6] Fisher, R.A., On the interpretation of chi-square from contingency tables, and the calculation of P, Journal of the Royal Statistical Society 85(1):87-94 (1922)

Made with Nozzle